Allakos, Inc. is a high-risk pharmaceutical company based in the United States of America. They specialize in developing therapeutic antibodies that selectively target immunomodulatory receptors on immune effector cells related to allergic, inflammatory, and proliferative diseases. Their lead program, AK006, focuses on targeting Siglec-6 to reduce mast cell activation. With an ESG score of 32.8, Allakos, Inc. is committed to environmental sustainability and governance.